Podcasts about Io

La NATO pianifica un attacco preventivo contro le minacce ibride russe: davvero stiamo rischiando la Terza Guerra Mondiale?Se la politica italiana non capisce la guerra moderna, le infrastrutture digitali rischiano attacchi informatici devastanti e campagne di disinformazione già da oggi: un solo attacco cyber può bloccare interi servizi pubblici e causare perdite di oltre 20 milioni di euro in 24 ore. Prevenire in modo proattivo è legge strategica: chi aspetta di reagire… perde in partenza. E questo è il significato, per me corretto, delle parole dell'Ammiraglio NATO Giuseppe Cavo Dragone.La difesa preventiva non è un attacco, è una protezione necessaria nell'era digitale.~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

Io sono Francesco Cecchetti, consulente paesaggistico e agronomico e aiuto le persone a fiorire insieme al proprio giardino. Stai ascoltando Giardino Rivelato, dal 2019 il podcast per chi crede fermamente che tutte le persone hanno bisogno di un giardino.  Veniamo da un'epoca che valuta tutto in base alla funzione. Così, il giardino diventa un peso. Ma la sua essenza è un'altra: è l'arte performativa più lenta, lo spazio per sperimentare e accogliere la natura. È tempo di cambiare racconto.Sostieni e finanzia Giardino Rivelato: https://www.patreon.com/francescocecchetti Vieni a trovarmi su giardinorivelato.it

durée : 00:26:48 - Les Midis de Culture - par : Marie Labory - Aujourd'hui, dans le débat critique, nous parlerons de littérature étrangère avec deux romans : "Les Fleuves du ciel" de l'écrivaine turque Elif Shafak paru chez Flammarion le 20 août ; et "Le jardinier et la mort" de l'écrivain bulgare Guéorgui Gospodinov paru chez Gallimard le 28 août. - réalisation : Laurence Malonda - invités : Virginie Bloch-Lainé Productrice à France Culture, critique littéraire, romancière. ; Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O

durée : 00:13:33 - Les Midis de Culture - par : Marie Labory - Avec "Le jardinier et la mort", Guéorgui Gospodinov signe un récit bouleversant où un fils tente de dire l'amour qu'il portait à son père disparu. Entre mémoire intime et héritage silencieux, le grand auteur bulgare explore la délicatesse des liens paternels. - réalisation : Laurence Malonda - invités : Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O; Virginie Bloch-Lainé Productrice à France Culture, critique littéraire, romancière.

durée : 00:13:15 - Les Midis de Culture - par : Marie Labory - Dans "Les fleuves du ciel", Elif Shafak entremêle trois destins séparés par les siècles mais unis par la mémoire de l'eau. De Londres à la Mésopotamie, elle signe un roman qui célèbre la résilience et la puissance de la mémoire. - réalisation : Laurence Malonda - invités : Virginie Bloch-Lainé Productrice à France Culture, critique littéraire, romancière. ; Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O

In quella stessa ora Gesù esultò di gioia nello Spirito Santo e disse: «Ti rendo lode, o Padre, Signore del cielo e della terra, perché hai nascosto queste cose ai sapienti e ai dotti e le hai rivelate ai piccoli. Sì, o Padre, perché così hai deciso nella tua benevolenza. Tutto è stato dato a me dal Padre mio e nessuno sa chi è il Figlio se non il Padre, né chi è il Padre se non il Figlio e colui al quale il Figlio vorrà rivelarlo». E, rivolto ai discepoli, in disparte, disse: «Beati gli occhi che vedono ciò che voi vedete. Io vi dico che molti profeti e re hanno voluto vedere ciò che voi guardate, ma non lo videro, e ascoltare ciò che voi ascoltate, ma non lo ascoltarono».

Die zwölfte Io.Co-Show: Unterhalter Gianluca Iocolano entlockt Karoline Uccelli noch nie Gesagtes

Dal Vangelo secondo LucaIn quella stessa ora Gesù esultò di gioia nello Spirito Santo e disse: «Ti rendo lode, o Padre, Signore del cielo e della terra, perché hai nascosto queste cose ai sapienti e ai dotti e le hai rivelate ai piccoli. Sì, o Padre, perché così hai deciso nella tua benevolenza. Tutto è stato dato a me dal Padre mio e nessuno sa chi è il Figlio se non il Padre, né chi è il Padre se non il Figlio e colui al quale il Figlio vorrà rivelarlo».E, rivolto ai discepoli, in disparte, disse: «Beati gli occhi che vedono ciò che voi vedete. Io vi dico che molti profeti e re hanno voluto vedere ciò che voi guardate, ma non lo videro, e ascoltare ciò che voi ascoltate, ma non lo ascoltarono».

The 2025 AHA Guidelines for CPR and Emergency Cardiovascular Care introduce significant updates, including a focus on on-scene resuscitation, cautious use of mechanical CPR devices, and prioritizing IV over IO access. While these changes aim to improve outcomes, they've sparked debate among seasoned paramedics like Jimmy Apple, the “EMS Avenger,” who highlights the challenges of implementation.   Key Points: • On-Scene Resuscitation: Emphasis on achieving ROSC on scene rather than rapid transport. • Mechanical CPR Devices: AHA advises against routine use, but paramedics argue they're essential for small or rural teams. • IV vs. IO Access: IV is prioritized, but practicality for resource-limited teams is questioned. • Empowering EMS Providers: Focus on critical thinking, quality compressions, and timely defibrillation. • Cultural Shift: Training crews for compassionate death notifications and clear family communication.

Crash GMs Cypher System for Beth, Ellie, Io, & Jen. This session: Our adventure begins on the first day of the Holy Convocation, an event where incarnations of the local deities gather together to NOT be horribly killed. Follow this series on… RSS: https://aaronbsmith.com/cogwheel/tag/cogworld-s1/feed/ Patreon: https://www.patreon.com/cogwheelgaming Mastodon: https://is.aaronbsmith.com/@cogwheel Not on Mastodon? Consider these instances: gamepad.club dice.camp mastodon.art chirp.enworld.org tabletop.vip MP3 Download: Cogworld S1 Ep 01: Convocation (Cypher System) Music Used: “Christofori’s Dream” by christofori is licensed as Public Domain and can be downloaded from http://modarchive.org Keep us ad free by supporting us on Patreon! Thanks to our current Patreon Patrons (as of this upload…): Cindy (Patron Emeritus), Ellie, Liv Dromen, ShanShen, and Walter!

IAD Talks - týždenné spravodajstvo. Spoločnosť Novo Nordisk opätovne čelí kombinácii problémových faktorov, ktoré sa dotýkajú jej postavenia na globálnej farmaceutickej scéne. Spoločnosť oznámila, že jej experimentálny liek na Alzheimerovu chorobu nepreukázal očakávaný efekt. Viac o tejto téme si môžete vypočuť v našom pravidelnom komentári z finančných trhov...IAD TALKS, týždenník, IAD Investments, správ. spol., a.s., Malý trh 2/A, 811 08 Bratislava, IČO: 17 330 254, dátum vydania: 1.12.2025, 55/2025, EV 139/23/EPP..*UPOZORNENIE. Tento materiál je marketingovým oznámením. Kompletné znenie upozornenia nájdete na stránke www.iad.sk/marketingoveoznamenia

L'intelligenza artificiale è una bolla finanziaria destinata a scoppiare?Tra il 2024 e il 2030 si giocheranno 7.000 miliardi di dollari: gli investimenti “circolari” tra giganti tech e startup rischiano di gonfiare artificialmente un mercato che potrebbe collassare tutto insieme. Se solo uno dei grandi player (Microsoft, NVIDIA, Oracle) fallisce, l'intero settore può crollare a catena: è già successo nel 2008 — questa volta i numeri sono 10 volte superiori.La vera domanda: bolla o rivoluzione? Il primo shock esterno può fare saltare tutto: quale sarebbe l'impatto per startup, lavoratori e investitori, e chi paga davvero il conto?~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

Capita di frequente, e a molti, di ritenere che la scienza e la sapienza di questo mondo possano spalancare tutte le porte del sapere, anche quelle del cielo. Non accade però mai così; anzi, il Signore smentisce categoricamente questa umana presunzione e, esultando nello Spirito Santo, afferma: «Io ti rendo lode, Padre, Signore del cielo e della terra, che hai nascosto queste cose ai dotti e ai sapienti e le hai rivelate ai piccoli. Sì, Padre, perché così a te è piaciuto». Essere “piccoli” agli occhi di Dio significa adornarsi di quella interiore semplicità che rende disponibili all’ascolto, docili e pronti a eseguire la volontà divina. I piccoli vivono in purezza e semplicità di cuore, si nutrono di fede, accettano i doni di Dio e a questi conformano la propria vita. Così viene loro rivelata l’essenza stessa di Dio, il suo infinito amore di Padre, manifestato in Cristo. Vivono nello splendore di Dio e conseguono la santità. Sono invece frequenti le presunzioni umane, quelle che ci inducono a voler guardare Dio e le cose di Dio solo con la ragione; così ci si autocondanna a un inevitabile naufragio della fede, che sconfina spesso nel naufragio della vita. La vera dottrina, la vera sapienza, quella che viene dallo Spirito Santo, ci consente di varcare i confini del mondo e ci proietta verso le verità ultime, oggetto della nostra fede, della nostra speranza e della nostra attesa.

In quella stessa ora Gesù esultò di gioia nello Spirito Santo e disse: "Ti rendo lode, o Padre, Signore del cielo e della terra, perché hai nascosto queste cose ai sapienti e ai dotti e le hai rivelate ai piccoli. Sì, o Padre, perché così hai deciso nella tua benevolenza. Tutto è stato dato a me dal Padre mio e nessuno sa chi è il Figlio se non il Padre, né chi è il Padre se non il Figlio e colui al quale il Figlio vorrà rivelarlo". E, rivolto ai discepoli, in disparte, disse: "Beati gli occhi che vedono ciò che voi vedete. Io vi dico che molti profeti e re hanno voluto vedere ciò che voi guardate, ma non lo videro, e ascoltare ciò che voi ascoltate, ma non lo ascoltarono".

In this episode of the Oncology Brothers podcast, we dive into the rapidly evolving landscape of renal cell carcinoma (RCC) treatment, focusing on second-line therapies. We were joined by Dr. David Braun, a GU Medical Oncologist from Yale University, to discuss two challenging real-life cases. We explored the current standard of care for metastatic RCC, including the use of immune-oncology (IO) therapies and tyrosine kinase inhibitors (TKIs). Dr. Braun shared insights on treatment options following disease progression, the importance of understanding disease biology, and the nuances of NCCN guidelines. Key topics included: • The role of TKI options like Axitinib, Cabozantinib, and Tivozanib in second-line treatment • The impact of disease progression on treatment decisions • Side effect management and the importance of palliative care • The potential use of HIF-2 alpha inhibitors like Belzutifan in specific scenarios Join us for an informative discussion that emphasized patient-centered care and the significance of shared decision-making in oncology.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ If you enjoy our conversations, please leave us a review and let us know what topics you'd like us to cover in future episodes! Stay tuned for more insights into the rapidly evolving field of cancer treatment. We are the Oncology Brothers! #RCC #KidneyCancer #TKI #Immunotherapy #OncologyBrothers #GUOncology

Ti è mai capitato di non sapere se usare l'imperfetto o il passato prossimo quando racconti una storia in italiano? In questa guida completa scoprirai gli argomenti grammaticali più importanti per padroneggiare il livello B1-B2, quelli che ti permetteranno di parlare italiano con maggiore precisione e sicurezza, evitando gli errori più comuni. Gli Argomenti Essenziali per il Livello B1-B2 dell'Italiano 1. Imperfetto vs Passato Prossimo: La Battaglia dei Tempi Questa è la domanda da un milione di euro per qualsiasi studente di italiano! La distinzione tra questi due tempi verbali rappresenta uno degli ostacoli più significativi nell'apprendimento della lingua italiana, ma una volta compreso il meccanismo, diventerà naturale scegliere quello corretto. Il Passato Prossimo Il passato prossimo si utilizza per indicare un'azione completata, con un inizio e una fine chiari e definiti. Quando dici "Ieri ho mangiato una pizza", stai comunicando che l'azione è stata portata a termine: la pizza è stata consumata completamente e l'evento è concluso. L'Imperfetto L'imperfetto, invece, descrive un'azione in corso, un'abitudine passata o una descrizione di stati e situazioni. Per esempio: "Da piccolo mangiavo sempre la pizza il venerdì" esprime un'abitudine ripetuta nel tempo, mentre "Mentre mangiavo, è squillato il telefono" presenta un'azione in corso che viene interrotta da un evento specifico. Esempi Pratici di Utilizzo Considera questa frase complessa: "Quando ero piccolo [descrizione dello stato], abitavo a Roma [abitudine]. Un giorno ho deciso [azione specifica e conclusa] di trasferirmi a Milano." In questo esempio, puoi osservare come l'imperfetto crei lo sfondo narrativo mentre il passato prossimo introduce l'azione che spezza questa continuità. Tempo VerbaleFunzioneEsempioPassato ProssimoAzione completata e puntuale"Ieri ho comprato un libro"ImperfettoAzione abituale"Da bambino leggevo ogni sera"ImperfettoDescrizione/stato"La casa era grande e luminosa"ImperfettoAzione in corso (sfondo)"Mentre dormivo, è arrivato Marco" 2. L'Accordo del Participio Passato: Le Regole Fondamentali Questo argomento terrorizza molti studenti, ma è più semplice di quanto tu possa pensare una volta comprese le regole di base. L'accordo del participio passato segue schemi precisi che, una volta interiorizzati, diventeranno automatici. Accordo con l'Ausiliare ESSERE Quando il verbo ausiliare è ESSERE, il participio passato si accorda sempre con il soggetto in genere e numero. Questa regola non ammette eccezioni: "Maria è andata" (femminile singolare) "I ragazzi sono partiti" (maschile plurale) "Le ragazze sono arrivate" (femminile plurale) Accordo con l'Ausiliare AVERE Con l'ausiliare AVERE, di norma il participio passato rimane invariato: "Ho mangiato", "Abbiamo studiato", "Hanno lavorato". Tuttavia, esiste un'eccezione fondamentale che riguarda i pronomi diretti. L'Eccezione con i Pronomi Diretti LO, LA, LI, LE Quando i pronomi diretti LO, LA, LI, LE precedono il verbo, il participio passato deve accordarsi con il pronome: "La pizza? L'ho mangiata!" (accordo con LA pizza, femminile singolare) "I libri? Li ho letti!" (accordo con I libri, maschile plurale) "Le scarpe? Le ho comprate!" (accordo con LE scarpe, femminile plurale) PronomeGenere/NumeroEsempioLOMaschile singolare"Il caffè? Lo ho bevuto" → "L'ho bevuto"LAFemminile singolare"La torta? La ho mangiata" → "L'ho mangiata"LIMaschile plurale"I documenti? Li ho firmati"LEFemminile plurale"Le lettere? Le ho spedite" 3. I Connettivi Complessi: Parlare Come un Madrelingua I connettivi rappresentano il segreto per sembrare fluente in italiano. Abbandonare la ripetizione continua di "e, e, e..." e passare a connettivi più sofisticati trasforma immediatamente la qualità del tuo discorso, rendendolo più elegante e strutturato. Connettivi per Aggiungere Informazioni Quando vuoi aggiungere informazioni a quanto già detto, puoi utilizzare diverse espressioni che arricchiscono il tuo discorso: Inoltre, per di più, oltretutto: "Quel film è noioso. Inoltre, è troppo lungo!" Non solo... ma anche: "Non solo è bella, ma anche intelligente" In aggiunta, peraltro: "Il ristorante ha ottimi piatti. In aggiunta, i prezzi sono ragionevoli" Connettivi per Esprimere Contrasto Per esprimere un'opposizione o contrasto tra due idee, l'italiano offre numerose possibilità: Tuttavia, però, eppure: "Studia molto, tuttavia non prende bei voti" Mentre, invece: "Io amo il caffè, mentre tu preferisci il tè" Al contrario, d'altra parte: "Pensavo fosse facile. Al contrario, si è rivelato molto complesso" Connettivi per Indicare Conseguenza Per collegare una causa al suo effetto, utilizza i connettivi di conseguenza: Perciò, quindi, dunque: "Piove, perciò prendi l'ombrello" Di conseguenza, pertanto: "Non ha studiato, di conseguenza è stato bocciato" Per questo motivo, ecco perché: "Era stanco. Per questo motivo è andato a dormire presto" FunzioneConnettivi FormaliConnettivi InformaliAggiuntaInoltre, per di più, in aggiuntaAnche, e poi, pureContrastoTuttavia, nonostante ciò, eppurePerò, ma, inveceConseguenzaPertanto, di conseguenza, dunqueQuindi, perciò, cosìCausaPoiché, dato che, in quantoPerché, siccome, visto che 4. Le Preposizioni Articolate: Quando le Preposizioni si Uniscono agli Articoli Le preposizioni articolate nascono dalla fusione tra le preposizioni semplici (di, a, da, in, su) e gli articoli determinativi. Questa combinazione è una caratteristica distintiva della lingua italiana e richiede una conoscenza approfondita per essere padroneggiata. Schema Completo delle Preposizioni Articolate +ILLOLAL'IGLILEDIdeldellodelladell'deideglidelleAalalloallaall'aiaglialleDAdaldallodalladall'daidaglidalleINnelnellonellanell'neineglinelleSUsulsullosullasull'suisuglisulle Usi Principali delle Preposizioni Articolate Ogni preposizione articolata mantiene il significato della preposizione semplice da cui deriva: DEL, DELLA, DEGLI, DELLE: esprimono possesso o appartenenza → "Il libro del professore", "La casa della nonna" AL, ALLA, AI, ALLE: indicano direzione o destinazione → "Vado al cinema", "Scrivo alla direttrice" DAL, DALLA, DAI, DALLE: esprimono provenienza o moto da luogo → "Vengo dal medico", "Torno dalla palestra" NEL, NELLA, NEI, NELLE: indicano stato in luogo chiuso → "Il gatto è nel giardino", "Viviamo nella città" SUL, SULLA, SUI, SULLE: esprimono posizione sopra → "Il libro è sul tavolo", "Cammino sulla spiaggia" Casi Particolari con i Nomi di Paesi Con i nomi di nazioni esistono regole specifiche da rispettare: Paesi singolari: "Vado in Italia", "Vivo in Francia" (senza articolo) Paesi plurali: "Vado negli Stati Uniti", "Viaggio nei Paesi Bassi" (con preposizione articolata) Paesi con articolo obbligatorio: "Vado nel Regno Unito", "Viaggio nella Repubblica Ceca" 5. Pronomi Diretti e Indiretti: Comprendere Chi Fa Cosa a Chi I pronomi sostituiscono i nomi per evitare ripetizioni e rendere il discorso più fluido. La distinzione tra pronomi diretti e indiretti è fondamentale per costruire frasi corrette in italiano. I Pronomi Diretti I pronomi diretti rispondono alle domande "che cosa?" o "chi?" e sostituiscono il complemento oggetto diretto: PersonaSingolarePlurale1ª personaMI (me)CI (noi)2ª personaTI (te)VI (voi)3ª persona maschileLO (lui/esso)LI (loro/essi)3ª persona femminileLA (lei/essa)LE (loro/esse) Esempio pratico: "Vedi Marco?" → "Sì, lo vedo" (vedo CHI? Marco = LO) I Pronomi Indiretti I pronomi indiretti rispondono alla domanda "a chi?" e sostituiscono il complemento di termine: PersonaSingolarePlurale1ª personaMI (a me)CI (a noi)2ª personaTI (a te)VI (a voi)3ª persona maschileGLI (a lui)GLI/LORO (a loro)3ª persona femminileLE (a lei)GLI/LORO (a loro) Esempio pratico: "Telefoni a Maria?" → "Sì, le telefono" (telefono A CHI? A Maria = LE) Come Distinguere Quale Pronome Usare Per capire quale pronome utilizzare, formula una domanda sulla frase: "Mangio la mela" → "Mangio che cosa?" → LA mela → "La mangio" (pronome diretto) "Parlo a Giovanni" → "Parlo a chi?" → A Giovanni → "Gli parlo" (pronome indiretto) 6. I Pronomi Combinati: Quando i Pronomi Vanno in Coppia I pronomi combinati rappresentano una delle sfide più impegnative per gli studenti di italiano. Si utilizzano quando nella stessa frase compaiono sia un pronome indiretto ("a chi") sia un pronome diretto ("che cosa"). La Formazione dei Pronomi Combinati Quando i pronomi si combinano, subiscono delle trasformazioni: MI, TI, CI, VI diventano → ME, TE, CE, VE GLI e LE (singolari) diventano entrambi → GLIE- (seguito da LO, LA, LI, LE, NE) Schema Completo dei Pronomi Combinati +LOLALILENEMIme lome lame lime leme neTIte lote late lite lete neGLI/LEglieloglielaglieliglieleglieneCIce loce lace lice lece neVIve love lave live leve ne Esempi Pratici di Utilizzo "Do il libro a Marco" → "Glielo do" (GLI = a Marco, LO = il libro) "Presto la macchina a te" → "Te la presto" "Racconto la storia a loro" → "Gliela racconto" "Compro i fiori per mia madre" → "Glieli compro" "Porto le chiavi a voi" → "Ve le porto" 7. CI e NE: Le Particelle Pronominali Multifunzione Queste due piccole parole possiedono una versatilità straordinaria nella lingua italiana. Comprendere i loro molteplici usi è essenziale per raggiungere un livello avanzato di competenza linguistica. Le Funzioni della Particella CI La particella CI può sostituire diversi elementi nella frase: Un luogo (complemento di stato o moto a luogo): "Vai a Roma?" → "Sì, ci vado domani" Un argomento introdotto da "a": "Credi ai fantasmi?" → "No, non ci credo"

Il brano “Io come te” nasce inizialmente dalla storia di due fratelli di cui è uscito anche un film ispirato a loro tratto da un libro che hanno scritto. Il ritornello è nato dal fatto che tra le tante citazioni fatte da loro durante i vari interventi che hanno fatto quando sono stati chiamati c'è […]

[Arabic: Three hundred and ninety-five – Practice makes perfect] Summer is just about to hit, so what better time to line up a show made for dancing to? Michael and Io get up and moving to these bangers in languages other than English. Whether you’re ready for the club, or can only manage a right foot in, out and shaken about – this one’s for you. Liked a particular track? Click the link to check out the video. And don’t forget to follow across social media: Facebook | X (Twitter) | Threads قائمة التشغيل Mitch Tambo – Hokey Pokey [Gamilaraay]        JO ft Anca Dinicu, Ioana State, Miruna Rumina, Tina Duceac, Ana Petcu & Anisia Gafton – Ne place [Romanian: We like it]        RESCENE – Bloom [Korean]        Sara Siipola – Haluun elää [Finnish: I want to live]        JACE – 是那麼聲勢浩大 LOUD & PROUD [Cantonese: It was so grand]        babble2babble: Arabic Vanco & AYA – Ma Tnsani (Yalla Habibi) [Don’t forget me (Come on, my love)]        Mohamed Ramadan – معاك للصبح [With you until morning]        Cleo & Donatan – Sianokosy [Polish: Haymaking]        Katarina Živković – Surova realnost [Serbian: Harsh reality]        Kuve – LLORAR-T [Spanish: Cry for you]        The post ثلاثمائة وخمسة وتسعين – التكرار يعلّم الحمار appeared first on babble POP!.

Netflix usa il de-aging AI in Stranger Things 5 per far tornare un 21enne… undicenne!Se la tecnologia ringiovanisce Noah Schnapp, presto i “fantasmi digitali” degli attori potrebbero lavorare per sempre. Il rischio? Violare diritti e togliere ruoli ai nuovi talenti: oggi è solo CGI, domani basta un click per sostituire chiunque.Siamo all'inizio di un'epoca di grandi produzioni che potrebbero ricreare attori AI, cambiando il lavoro nel cinema per sempre.~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

Artificial Intelligence and Machine Learning in Human Resources: A Concise Guide by Dr. C. Rasmussen https://www.amazon.com/Artificial-Intelligence-Machine-Learning-Resources/dp/B0FWZQXHMG Curtisrasmussen.focalpointcoaching.com What if a computer could help find the perfect employee or predict who might leave a job? This exciting idea opens the door to a new way of working. Overview This guide explains how artificial intelligence (AI) and machine learning (ML) are transforming human resources (HR). Smart computer programs can quickly review thousands of job applications to find the best candidates, suggest training tailored to employees’ needs, and predict which workers might quit, helping managers take action to keep them. The book includes real-world examples, like how large companies use AI to save time, and covers benefits, such as improved hiring, as well as key concerns, like protecting personal information. At just 61 pages, it's concise by design, following Richard Feynman's wisdom: “If you can’t explain something simply, you don’t understand it well enough.” More pages don't equal more value; in fact, lengthy texts can bury useful insights. Since every organization is unique, this book equips HR professionals and managers with the right questions to ask rather than a rigid roadmap, making it a practical tool for anyone curious about the future of work. About the author Dr. Curtis “Curt” Rasmussen is a leading expert in industrial-organizational psychology with a Ph.D. from Walden University. He specializes in blending human skills with artificial intelligence (AI) and machine learning (ML) to make workplaces better and more efficient. With years of experience in research, consulting, and government roles, he helps businesses use data and tech wisely. His career highlights include owning Cyber-Human Performance Tech, LLC, where he advises small and mid-sized companies on adding AI to hiring and daily tasks while keeping things ethical. He also guides students in George Mason University’s Data Engineering program, focusing on AI tools like natural language processing and computer vision. At the Cybersecurity and Infrastructure Security Agency (CISA), he led workforce planning as a senior I/O psychologist, creating surveys and frameworks that improved employee satisfaction by 45% and helped with smarter hiring. Earlier, he reviewed AI and data science proposals for the Department of Commerce, National Academy of Medicine, and the Office of the Director of National Intelligence, making sure projects were strong and fair. Dr. Rasmussen has invented patent-pending tools like the Multidimensional Algorithm Structure (MAS), which picks the best AI methods by checking data and company needs, and the eXplainable Artificial Intelligence Construct (XAIC), which makes AI easy to understand and trust by involving people in decisions. These ideas help fix common AI problems, like failures or hidden biases.

Con il nostro Claudio Chiari è tornata a trovarci un'amica di Radio Number One: Anna Maria Barbera! La nota attrice e comica terrà uno spettacolo venerdì 5 dicembre al Teatro Manzoni di Monza dal titolo "Noi, nonostante tutto", che riprende il progetto "Io nonostante tutto" promosso dall'ASI, Asso Style Image. Una serata a scopo benefico (il ricavato andrà proprio al progetto benefico) di cui Radio Number One è media partner: «La protagonista di questo evento è la causa per cui facciamo questo spettacolo - ha raccontato Anna Maria Barbera -: più persone ci saranno, più saranno gli spiccioli che daremo alle ragazze dell'associazione che ogni giorno dedicano il proprio tempo al sostegno psicologico delle persone quando ricevono una diagnosi oncologica».

L'Intelligenza Artificiale sta riscrivendo le regole dell'advertising.Da un lato offre una personalizzazione senza precedenti , dall'altro rischia di creare un ''inquinamento digitale'' fatto di contenuti di bassa qualità che minano la fiducia degli utenti.Ne parlo con Carlo Noseda, Presidente di IAB Italia. Con lui analizziamo lo stato dell'arte del mercato: dalla concentrazione degli investimenti nei grandi ''Walled Garden'' alla necessità di tutelare un Open Web democratico, dal cambio di paradigma della semplice ''Viewability'' alla ''Attention Economy'' e di come usare l'IA ''a valle'' per potenziare la creatività, anziché ''a monte'' per generare mediocrità.Per scoprire se il marketing sta diventando pura manipolazione algoritmica o c'è spazio per la qualità!~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

A crowded server board with ten thousand parts doesn't forgive sloppy inspection—and neither do pricey GPUs and chiplets. From the floor of Productronica in Munich, we dig into how automated optical inspection keeps advanced packages honest once they hit the PCB line, where solder quality, coplanarity, and sheer component variety can make or break yield. Vidya Vijay from Nordson Test & Inspection joins us to unpack why AOI remains the fastest path to actionable insight, when X‑ray is the smarter choice, and how new sensor design changes the game for reflective, high‑mix assemblies.We explore the real pain points engineers face today: shiny dies that confuse cameras, BGAs packed with I/O where hidden defects hide under the body, and miniature passives that crowd tight keep‑outs. Vidya explains how three‑phase profilometry creates true 3D height maps by projecting fringe patterns and reading them from multiple angles, enabling precise checks for corner fill, underfill, and coplanarity. We also get into multi‑reflection suppression, Nordson's approach to filtering glare and ghost images so the system sees the joint, not the noise. With true RGB on side cameras and higher resolution, AOI can now pick out tiny solder balls and subtle surface issues at speed—fuel for stronger AI autoprogramming and more reliable defect classification.If throughput is king, data is queen. We talk about closing the loop from inspection back to the line to prevent bad lots—flagging stencil drift, placement offsets, and paste issues before they explode into scrap. Then we spotlight Nordson's launched SQ5000 Pro: faster cycle times, a wider field of view, and configurable 7 µm or 10 µm sensors designed for modern PCBA demands. Whether you're chasing yield on high‑value GPUs or balancing AOI with AXI on dense boards, this conversation offers a practical roadmap for choosing the right tool, tackling reflectivity, and using insight to drive predictable quality.Nordson Test and Inspection Delivering best-in-class test, inspection, and metrology solutions for semiconductor applications. Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the show

Io adoro la Sicilia, e tu? Scopri insieme a me tante curiosità. Trascrizioni ed esercizi su www.podcastquattrostagioni.ch

Look kids, this is where the rubber meets the road. It's Black Friday. It's Rivalry Week. It's the HyVee Heroes Trophy. Dammit, I hate that trophy. I hate Io_a. I'm developing a healthy distrust of holidays in general, and you edge lords of the internet are starting to win me over to your side in this annual campaign of not only self-loathing, but a deep and perennial lack of enthusiasm about our so-called "beloved" Cornhuskers. Why don't we kick field goals to take early points? Why do we run the ball up the middle five godforsaken times in a row inside the opponents' ten yard line? Why can't we have nice things? And why is it that each Black Friday we have this corporate buffoonery where we have to endure a rock fight with a joke program with even worse fans who are so incompetent they didn't even know they had a Heisman Trophy winner, and their joke of a stadium is named after him?!? I mean seriously, Kinnick Stadium. Their boring brand of football has elevated them to the peak of mediocrity. "They are who we thought they are." And they'll never be anything greater. It's Thanksgiving Eve. It's Turkey Before Turkey. To hell with Io_a. Let's drink.

«Sono fiero dello sviluppo della città, ma certe notizie mi fanno arrabbiare» — (integrale su cdtlink.ch/ex-sindaco con tanto di videointervista) — L'ex sindaco di Locarno, Alain Scherrer, a tutto campo dopo un periodo di silenzio «per avere il giusto distacco»: dalle aggregazioni al Film Festival che chiede di cambiare le date, al ricorso sui concerti estivi — «Seguo la politica e preferisco farlo con un certo distacco, perché voglio rispettare le scelte della compagine che ha preso posto a Palazzo Marcacci». «Sì, ora accetto con grande piacere il vostro invito, prima mi pareva prematuro». Alain Scherrer è in formissima e ha scelto Palazzo Marcacci come luogo simbolo per ambientare un'intervista a tutto campo da rilasciare in esclusiva al Corriere del Ticino. «Sono stati gentili, abbiamo la possibilità di starcene nientemeno che nella sala del Municipio, dove ho lasciato un pezzo del mio cuore», afferma carico d'entusiasmo con il suo immancabile sorriso, salutando la ragazza allo sportello della cancelleria. «Credo sia passato il tempo necessario per poter rispondere alle vostre domande senza voler apparire invadente», aggiunge mentre sale le scale a passo spedito verso la stanza dove per lungo tempo ha retto il timone della Città di Locarno. Una volta entrato, si guarda in giro e indica con emozione il suo posto, «a capotavola». Sono passati quasi due anni dalle elezioni comunali del 14 aprile 2024, dalle quali è scaturita la nuova composizione dell'Esecutivo, rinnovato per quattro settimi. Il nostro interlocutore, all'epoca, aveva annunciato con largo anticipo di non volersi ricandidare.«Il nuovo Municipio? Mi piace questa squadra. Conosco molti di loro: chi ha già vissuto questa casa e chi ora vi entra con entusiasmo. Hanno visione, competenza, e soprattutto il mio successore ha un vero senso dello Stato, orientamento strategico, conoscenza profonda delle tematiche e il suo saper fare è lucido e concreto. Li vedo lavorare con serietà, e ho fiducia. È un sentimento raro, e me lo tengo stretto». Il neo sessantenne («Ma non mi sento vecchio, eh? Facciamo solo... meno giovane di prima, dai») riavvolge il nastro del tempo: «Ho cominciato a fare il sindaco proprio il giorno del mio cinquantesimo compleanno. Nove anni intensi. E se ci mettiamo anche i tempi in Municipio, sono quasi vent'anni. Vent'anni passati dentro queste stanze: riunioni interminabili, notti di scelte pesanti, migliaia di pomeriggi spesi per la Città. E, credetemi, ogni ora è stata viva».Si apre, tuttavia, una nuova fase. Più «distaccata», se si può definire così: «Sto molto bene, ho tempo per me e per la famiglia. Quando sei immerso in un ruolo istituzionale così in vista, non ti rendi conto di quanto sia totalizzante. Solo quando ti fermi capisci quanto correvi. Sono orgoglioso della mia Città. Leggo i giornali, mi rallegro quando trovo belle notizie e m'arrabbio per quelle negative, che però adesso vivo in modo differente. Oggi le decisioni sono in mano alla nuova compagine e il mio auspicio è che le sue scelte siano sempre guidate dal bene per la popolazione e non da speculazioni elettorali», esclama, citando i progetti principali che contribuiranno al rilancio di Locarno, come la riqualifica di piazza Grande e Largo Zorzi, il centro congressuale, la Rotonda, il Castello e il Museo di storia naturale. «Mi rendo conto che abbiamo avviato tanti progetti, forse troppi pensando alla forza finanziaria della Città e ciò non rende facile il lavoro a chi siede oggi nell'Esecutivo».E, a proposito di «arrabbiature», sul tavolo di Bellinzona era stata consegnata, ancora nella precedente legislatura, l'istanza di aggregazione con Lavertezzo, insieme alla collega Tamara Bettazza. Qualche settimana fa - dopo il «cambio della guardia» primaverile che ha portato Andrea Berri alla guida del piccolo Comune - colpo di scena: questi appare in foto con l'omologo Damiano Vignuta, di Gordola, voltando le spalle al «matrimonio» previsto con Locarno e avviando un altro tra i loro due Comuni. «Con tutto il rispetto per i protagonisti, questa fotografia mi ha fatto male», dice con rammarico.«Ad ogni modo il merito è stato di riaprire il dialogo, soprattutto con Losone e Minusio, che sono interlocutori preziosi. Altri, invece, sembrano solo approfittare della centralità di Locarno, rivendicano autonomia ma poi non sono capaci di gestire i progetti importanti, come è accaduto a Muralto con il nodo intermodale alla stazione. La fusione degli enti locali attorno al nucleo dell'agglomerato urbano è a mio avviso inevitabile, dato che la frammentazione rallenta lo sviluppo». Note più positive (letteralmente) per un altro capitolo importante nella vita dell'intervistato. Da due decenni, infatti, canta nel complesso «Vasco Jam». «La musica, il palco: è la mia seconda famiglia. Il gruppo ha 41 anni ed è probabilmente la cover band di Vasco più longeva di sempre. È casa mia. Noi sul palco ci divertiamo, e la gente lo sente».Sempre in ambito musicale, ecco spuntare un ulteriore tasto dolente: il ricorso di un esercente di piazza Grande contro i concerti estivi: «Mi rattrista vedere chi antepone interessi personali all'estate di Locarno. Piazza Grande è un simbolo potente. Qui sono passati nomi che hanno lasciato memoria nel mondo. Non possiamo rischiare che qualcuno rovini tutto per egoismi». L'altro pilastro della bella stagione è il Festival, la manifestazione culturale più importante a livello nazionale. Che vorrebbe anticipare la programmazione. Un'opportunità da cogliere? «La questione è delicata. Capisco l'industria cinematografica, ma anche il turismo vive di equilibri delicati. Il calendario è un incastro prezioso. Il Festival è un pilastro: Locarno grazie a questa manifestazione vive di cultura».Infine, la politica. Perché è proprio il «suo» PLR ad aver perso il quarto seggio del distretto in Gran consiglio. «Sì, anni fa avrei voluto fare un'esperienza a livello cantonale. Ma oggi non ne sono più attratto. La politica, parlo in generale, non dialoga più con la vita reale. È incompatibile con il mio modo di intendere il servizio pubblico. Manca il cuore. Manca il coraggio. Manca la coerenza. Manca la concretezza. Si preferisce apparire invece di agire, inseguire consenso invece di assumersi responsabilità. È un mondo che si racconta, ma non costruisce più. Io non ci sto. Voglio continuare a fare del bene, ma non accanto ai giochi di potere. Non come sindaco, voglio farlo come uomo. E le persone, non i ruoli, fanno la differenza».

Beth GMs for Ellie, Crash, and Io. This episode: The Logistics Trio continue to follow breadcrumbs, this time exploring a ruined temple with odd things below the basement. Follow this series on… RSS: https://aaronbsmith.com/cogwheel/tag/gurpswars/podcast Patreon: https://www.patreon.com/cogwheelgaming Mastodon: https://is.aaronbsmith.com/@cogwheel Not on Mastodon? Consider these instances: gamepad.club dice.camp mastodon.art chirp.enworld.org tabletop.vip MP3 Download: GURPS Wars S1 Ep 84: Squelch Basement Music Used: “Cabin Fever!” by Drozerix is licensed as Public Domain and can be downloaded from http://modarchive.org. Keep us ad free by supporting us on Patreon! Thanks to our current Patreon Patrons (as of this upload…): Cindy (Patron Emeritus), Ellie, Liv Dromen, ShanShen, and Walter!

Shuli Branson joins Io to discuss Frankenstein! We talk about Mary Shelley's cool life and legacy and Guillermo Del Toro's (secret egg) take on her story. We also talk monstrosity, transness, parenthood and abolishing the family, prison, id and ego, what “life” is. You know, Frankenstein stuff. It's about an hour and a half of a professor and a clown talking Frankenstein stuff. Listen to Shuli's good ass podcast The Breakup Theory and check out their writing collective CAW www.cawshinythings.com Io is on the instagram @bum.lung and bluesky @citizenio. They also got a patreon now https://www.patreon.com/c/bumlung?view_as=patron&vanity=bumlung This show is published by Strangers in A Tangled Wilderness. We can be found at www.tangledwilderness.org, or on Twitter @TangledWild and Instagram @Tangled_Wilderness. You can support the show on Patreon at www.patreon.com/strangersinatangledwilderness. Our logo is by Robin Savage. And our theme music is by a lovely mountain goblin.

Acaban de dejarnos la cantante y actriz italiana Ornella Vanoni y el compositor, cantante y guitarrista brasileño Jards Macalé. Recordamos al artista carioca con grabaciones de 'Para ver as meninas' y 'Luz negra' (del disco '4 batutas e um coringa'), 'Vampiro de Copacabana', 'Buraco da consolação' y 'Obstáculos' (del disco 'Besta fera'), 'Movimento dos barcos y 'Vapor barato' (del disco 'O que eu faço é música') y 'Um abraço do João' (del disco de Joyce Moreno 'O mar é mulher'). Y a la artista milanesa en 'Io che amo solo te' y 'E penso a te', en adaptaciones al italiano de canciones de Roberto Carlos como 'L appuntamento' (Sentado à beira do caminho) o 'Se fosse vero' (Você não sabe') y con Vinicius de Moraes y Toquinho ('Samba della rosa', 'La voglia, la pazzia', 'Senza paura'). Escuchar audio

This show has been flagged as Clean by the host. Hello, again. This is Trey. Welcome to part 4 in my Cheap Yellow Display (CYD) Project series. If you have hung in there with me so far on this journey, thank you. If you have missed earlier episodes, you can find them on my HPR profile page https://www.hackerpublicradio.org/correspondents/0394.html If you have questions, comments, concerns, or other feedback, please leave an episode comment, or drop me an email (Using the address in my profile). Even better, you could record and upload your own show which shares your viewpoint or expertise. To review, I finally have an actual project to build using the CYD. It is a portable, programmable morse code "Keyer memory" which can be connected to any of my HF transceiver radios by simply plugging it in to the code key input port. Then I could transmit stored messages by simply touching their specific icon on the touch screen. So, now I purchased a pair of CYDs. Each arrived in an anti-static zipper bag with a USB C cable, a 6 inch long 4 pin PB1.25mm to Dupont 2.54mm cable harness, a plastic case holding the CYD itself and a small plastic stylus. There are pictures in the show notes. Depending on how many IO connections I may need, and how I plan to power this, I am probably going to need more 4 pin PB1.25mm wired connectors. You can see a description of the various features and connectors on RandomNerdTutorials writeup about this board ( https://randomnerdtutorials.com/cheap-yellow-display-esp32-2432s028r/ ). The only difference I can see between this description and what I received is that mine have both a MicroUSB and USB C port. Of course, first thing, I had to plug it in and see what happens. It appears to be running some kind of simulation of a web site. The backlit display looks alright. It is not super high resolution, but for the price, it will suite my needs. The touch screen is responsive, but it is pressure sensitive and works best using the provided stylus or a fingernail and not your finger tip. So, I have the CYD. What other hardware do I need? I need to address how one of these will actually connect to my radios. Modern amateur radio transceivers which support continuous wave (CW) transmission (Which is another name for Morse code) generally can use one of two different pieces of hardware for input. The first is what we call a straight key. Below is a photo of the one I own. This is a classic, old fashioned telegraph style code key. It is designed to quickly and easily be pressed down to close a circuit and when released the circuit is opened, effectively making it a normally open push button switch. To send a dot, the operator holds down the key for a short period of time, then releases it. To send a dash, the operator holds down the key for a longer period of time, before releasing it. (We will discuss actual timing specifications for morse code in a future podcast) Connectivity for the switch has been standardized to use a 3.5 mm mono male phone connector which has only sleeve and tip connections. The second option is a paddle style electronic keyer. There are many styles of these, and I am including a picture of the one I use, which once belonged to a close friend of mine who is now silent key. In general, the paddle is two separate normally open switches. In the most common configuration, if an operator presses and releases the paddle on the right, a dash is sent. If the paddle on the right is held, a continuous series of dashes will be sent until that paddle is released. The left paddle works similarly. If it is pressed and released, a single dot is sent. If it is pressed and held, a series of dots is sent until it is released. The function of these paddles can be swapped from left to right using the radio configuration. There is additional functionality which can be configured in some radios for when both paddles are pressed simultaneously, but I am not going to describe those here. The paddle generally uses a 3.5mm stereo male phone connector with the sleeve being common. The tip of the phone connector is wired to the left paddle and ring of the connector is wired to the right paddle. Most modern radios have a built in keyer which can be configured for a paddle and will automatically transmit the dots or dashes at whichever speed is configured based on the paddle pressed. You can see this phone connector illustrated on Wikipedia's phone connector page. . https://en.m.wikipedia.org/wiki/Phone_connector_(audio ) You can learn more about all the various devices which can be used for sending morse and how they function at Morse Code World . https://morsecode.world/keys.html Ideally, controlling all the morse code timing within the CYD would be best. That way, it could be connected as a straight key and any keyer settings already configured within the radio shouldn't matter. However, If I wish to also be able to manually send morse code myself using my paddles, without disconnecting the CYD and reconfiguring the radio, that could be problematic. I may need to factor in the possibility of connecting my paddle to the CYD and then building in code to respond to inputs from the paddles. As I mentioned in a previous episode, I have an Arduino Nano on my desk as a practice oscillator for my paddles. I may be able to reuse some of that code on the CYD. So, if I want the CYD to appear to the radio like a straight key, I will need it to be able to control a switch quickly and accurately. But I also want the CYD and the radio to be electrically isolated from each other. This calls for a relay. I was able to find and order some inexpensive relay modules which work nicely with Arduino and ESP32. These allow connectivity to 5v power and to one of the CYD's GPIO pins. These feed an optocoupler circuit, which, in-turn, drives the coil of the relay. This provides inductive kickback protection to the CYD and can drive a coil which would require more current than the GPIO can provide. Inductive kickback rabbit trail: An inductor is simply a coil of wire. Direct current flowing through any wire generates a magnetic field. Within the inductor, because the wire is coiled, the magnetic field builds from each pass of the wire in the coil. If you include an iron core, it sustains the magnetic field even better. This is the basis for an electro magnet. A relay is simply a momentary contact switch controlled by an electromagnet. One unique property of an inductor is that, current wants to keep flowing in the direction it was applied. To be specific, when the current source is removed, the magnetic field still exists for a while, and it effectively "generates" an electric current within the coil, in the same direction as the one which initially created the magnetic field to begin with. If it has a path to flow, this current will create another weaker magnetic field, which creates its own electric current, in a diminishing loop. If the circuit which drives the coil of a direct current relay is not ready for this continued push of current, damage can be done. Many times this is countered by wiring a "flyback diode" in parallel with the coil and in the opposite direction in which current will be applied. This way, when the current source is stopped, the diode gives a path for the inductive kickback current to safely flow while the magnetic field dissipates. Explained in greater detail at https://inductive-kickback.com/2019/04/inductive-kickback-made-simple-to-grasp-easy-to-handle/ The switch side of the relay is a single pole double throw (SPDT) and makes connections available for common, normally closed (NC), and normally open (NO). It will be easy to connect the common and NO connections to a 3.5mm mono male connector so that it may be plugged into the "key" port on any radio transmitter. I will need to do some testing on the speed of the relay, but I think it will work just fine. Once I start writing some code for the CYD, I will be able to connect and test the relay. Well, this is a good place to end this episode, and it is one of the longest in this series so far. In the next episode, we will begin to look at how we design the user interface for our program, something I do not know anything about (yet). Stay tuned weekdays for additional exciting episodes of Hacker Public Radio, and, at some point, the next episode in this series. If you like what you have heard, please leave an episode comment, or drop me an email (Using the address in my profile). If you have more than a single sentence to contribute on the subject, I encourage you to record an episode with your thoughts and expertise. If you dislike what you have heard, you are encouraged even more strongly to record and upload your own show which shares your viewpoint or opinion. Until next time. Provide feedback on this episode.

durée : 00:13:01 - Les Midis de Culture - par : Marie Labory - Avec "Zoé [et maintenant les vivants]", Théo Askolovitch signe une seconde création intime où il revisite, dix ans après, le deuil de sa mère. Aux côtés de Serge Avédikian et Marilou Aussilloux, il tisse un récit familial sensible, mêlant souvenirs, rires et vertiges de l'absence. - réalisation : Laurence Malonda - invités : Victor Inisan docteur en études théâtrales, dramaturge et critique ; Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O

durée : 00:26:54 - Les Midis de Culture - par : Marie Labory - Aujourd'hui, au menu de notre débat critique du théâtre avec Pinocchio Creature d'après Carlo Collodi, adaptation et mise en scène de Sophie Bricaire à la Comédie Française & Zoé (et maintenant les vivants) de Théo Askolovitch au Théâtre de la Bastille - réalisation : Laurence Malonda - invités : Victor Inisan docteur en études théâtrales, dramaturge et critique ; Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O

durée : 00:12:45 - Les Midis de Culture - par : Marie Labory - Avec "Pinocchio créature", le célèbre pantin entre au répertoire jeune public de la Comédie-Française dans une mise en scène poétique de Sophie Bricaire. À travers le regard de Geppetto, le conte de Collodi devient un hymne à l'amour et à la création, mêlant aventures et humour. - réalisation : Laurence Malonda - invités : Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O; Victor Inisan docteur en études théâtrales, dramaturge et critique 

In this episode of JCO Article Insights, host Dr. Ece Cali Daylan interviews author Dr. Jeffrey Bradley about the article, "Simultaneous Durvalumab and Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer" by Bradley, et al published October 13, 2025. TRANSCRIPT Dr. Ece Cali: Welcome to this episode of JCO Article Insights. This is Dr. Ece Cali, JCO Editorial Fellow. Today I'm joined by Dr. Jeffrey Bradley, Professor of Radiation Oncology at the University of Pennsylvania, to discuss the manuscript, "Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small-Cell Lung Cancer: The Phase III PACIFIC-2 Study." The PACIFIC-2 study was a phase III, double-blind, randomized trial comparing the efficacy and safety of simultaneous durvalumab with concurrent chemoradiation followed by consolidation durvalumab to the concurrent chemoradiation followed by placebo in patients with unresectable stage III non-small cell lung cancer. The primary endpoint was progression-free survival by blinded independent central review. The secondary endpoints were overall response rate, overall survival, and safety. Three hundred twenty-eight patients were randomized 2:1 to durvalumab and placebo, respectively. Unfortunately, this trial did not meet its primary endpoint. There were no statistically significant differences in PFS or OS. The frequency of adverse events was similar between the two arms. Grade 3 or higher adverse events were observed in 53% of the patients in the durvalumab arm compared to 59% of the patients in the placebo arm. Of note, the frequency of pneumonitis was similar in the two arms. Approximately 28% of patients in each arm developed pneumonitis, and about 5% of the pneumonitis observed in each arm was grade 3 or higher in severity. Treatment discontinuation rates secondary to the adverse events were higher in the durvalumab arm, 25% compared to 12%. Adverse events leading to treatment discontinuation and death were more frequently seen in the durvalumab arm during the first four months of the treatment, which corresponds to the simultaneous administration of chemoradiation and durvalumab. Dr. Bradley, before we delve into the results, can you please explain the rationale for this study design and how this concept fits into the current treatment landscape? Dr. Jeffrey Bradley: Yeah, this trial came on the heels of PACIFIC after there was a progression-free survival benefit showed in PACIFIC that in the locally advanced unresectable population that consolidation immunotherapy, in this case durvalumab, had a progression-free survival benefit. A number of us in the clinical trial space thought to add concurrent immunotherapy in addition to consolidation immunotherapy that that would also improve outcomes for patients. So a number of trials were launched to follow up of PACIFIC. In this case, this is a phase III trial where the control arm was placebo. There was no overall survival results yet from PACIFIC, just a PFS benefit, and a number of countries across the world had not approved maintenance durvalumab in this space. So this trial looked at the experimental arm, which was concurrent immunotherapy, durvalumab, and chemoradiation followed by consolidation durvalumab versus placebo. Dr. Ece Cali: And if we were to focus on the safety profile first, an increased pneumonitis risk was a theoretical concern when immunotherapy is given concurrently with radiation. Do we see any major differences in the safety profile between the two arms in this trial? Dr. Jeffrey Bradley: No, and we were concerned about the addition of concurrent immunotherapy and chemoradiation, like you said, towards concern about increased pneumonitis rate, but we did not see increased pneumonitis in the experimental arm over placebo. And the grade 3 or higher, as you said, it was roughly 5%, more or less, in both arms, so we didn't see increase in pneumonitis toxicity with concurrent IO and chemoradiation. Dr. Ece Cali: But interestingly though, despite the lack of significantly increased toxicity with durvalumab, unfortunately, administering immunotherapy simultaneously with chemoradiation therapy did not improve survival. Lack of superiority of this treatment regimen, as you mentioned, is further confirmed across multiple similar negative trial readouts such as ECOG-ACRIN 5181 and CheckMate 73L. Dr. Bradley, in your view, what are some potential explanations for why this strategy did not pan out in clinical trials? Dr. Jeffrey Bradley: Regarding toxicity, let me go back and point out that we did see an increased number of immune-mediated adverse events. It was 34.7% in the concurrent immunotherapy arm versus 15.7% in the placebo arm. So that led to a higher number of discontinuations of immunotherapy which I think probably had an effect. So we didn't... there was an increased pneumonitis toxicity, but there were expected immune-mediated toxicities that caused people to stop giving immunotherapy. You can see that in the PFS curves. They were, you know, they crossed over after like a month, but initially there was lower PFS for the experimental arm, and then the experimental arm got better after we divided into four months, before four months and after four months. Dr. Ece Cali: For one reason or another, it looks like the simultaneous administration did not really improve outcomes. We now know that simultaneously giving them another concurrent radiation should really no longer be pursued in clinical trials for this patient population. Can you share with our audience what strategies are being studied in this setting and what trials to watch out for in the future? Dr. Jeffrey Bradley: Sure, I think when you add concurrent radiation to immunotherapy, there were more central tumors in this trial, I think you're killing lymphocytes and negating the effect of immunotherapy. So I think that's the smoking gun for this trial, for the ECOG trial, for the small cell trial that NRG reported, LU005, and other trials. So correct, I don't think there's any need to continue to pursue concurrent immunotherapy in this space of lung cancer. But that's not to say there aren't many other trials that are either ongoing, have accrued and awaiting results, or being planned for the next phase of clinical trials. We have a trial within NRG Oncology called NRG-LU008. It's a randomized phase III trial that is using an SBRT boost to a peripheral primary and chemoradiation to the nodes, because the primary tumor is the one that fails more often than the lymph nodes, and that's compared to PACIFIC in the control arm. PACIFIC-9 is another trial in the same line as the other PACIFIC trials. That one is using dual checkpoint inhibition versus the control arm being PACIFIC. So there are three arms in that trial, durva and oleclumab, durva and monalizumab versus the PACIFIC arm. And that trial is completed accrual, but we have no results from that study yet. Johnson & Johnson has a trial open looking at a nanoparticle. That's a radiosensitizer where bronchoscopy is used to inject the primary tumor and the lymph nodes with a radiosensitizer. That's a randomized phase ll trial that's ongoing. It's got three arms, two different doses of this radiosensitizing drug and then a control arm without injection at all. The control arm is again the PACIFIC arm. And then those of us within the NCI-based clinical trials evaluation program, CTEP, are proposing an intergroup trial that would compare induction chemo-immunotherapy followed by chemoradiation followed by maintenance immunotherapy versus PACIFIC in a phase III study. So I think there's other trials that are either completed, ongoing completed, or on the horizon to assess in this patient population. Dr. Ece Cali: Yeah, we definitely have an unmet need to improve survival outcomes for stage III patients, and it's great to hear that there are so many efforts looking at different strategies to improve outcomes for these patients.  Thank you so much, Dr. Bradley, for this informative discussion and for sharing your insights. Any last thoughts? Dr. Jeffrey Bradley: Yeah, we need something, you know. PACIFIC was first reported in 2017, and we really haven't made progress in terms of changing that standard of care control for the last eight years. So we need progress in this area. Dr. Ece Cali: Yep, definitely. Thank you so much for joining, Dr. Bradley.  And thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. DISCLOSURES Dr. Bradley Honoria: Mevion Medical Systems, Inc. Consulting or Advisory Role: Varian, Inc, Genentech, Inc. Research Funding: Varian Medical Systems Dr. Cali Research Funding Company: BeiGene, Nuvalent, Inc., Astra Zeneca 

Ellie GMs for Beth, Crash, Io, & Jen. This episode: The adventurers are hired to seal a dungeon so nothing can move back in. Of course, they have to clear it out first … Follow this series on… RSS: https://aaronbsmith.com/cogwheel/tag/plus-ultra-s2/feed/ Patreon: https://www.patreon.com/cogwheelgaming Mastodon: https://is.aaronbsmith.com/@cogwheel Not on Mastodon? Consider these instances: gamepad.club dice.camp mastodon.art chirp.enworld.org tabletop.vip MP3 Download: Plus Ultra S2 Ep 03: Matlock Tor by Daylight (Cypher System) Music Used: “The Digital Dragon” by Drozerix is licensed as Public Domain and can be downloaded from http://modarchive.org Keep us ad free by supporting us on Patreon! Thanks to our current Patreon Patrons (as of this upload…): Cindy (Patron Emeritus), Ellie, Liv Dromen, ShanShen, and Walter!

Con questa guida completa, scoprirai 6 film italiani perfetti per ogni livello di conoscenza della lingua, dal principiante assoluto (A1) fino all'esperto (C2). Prima di tutto, vedremo 2 film adatti ai livelli principianti (A1-A2), con dialoghi semplici e situazioni facili da capire. Poi ci occuperemo di 2 film per i livelli intermedi (B1-B2), dove la lingua diventa più naturale e ricca. E infine, esploreremo 2 film per i livelli avanzati (C1-C2), con linguaggio complesso e riferimenti culturali profondi. 6 Film per Imparare l'Italiano (Dal Livello A1 al Livello C2) Livello A1-A2: Principianti 1. "Io non ho paura" (2003) - Livello A1 Questo film di Gabriele Salvatores è un vero gioiello per chi inizia a studiare italiano! "Io non ho paura" racconta la storia di Michele, un bambino di 10 anni che vive in un piccolo paese del Sud Italia negli anni '70. Durante l'estate, giocando nei campi di grano con i suoi amici, Michele scopre un segreto terribile che cambierà la sua vita. Perché questo film è perfetto per il livello A1? Innanzitutto, il protagonista è un bambino, quindi molti dialoghi sono semplici e diretti, proprio come il linguaggio che si usa con i bambini. Le frasi sono brevi e chiare. I personaggi parlano lentamente e in modo comprensibile. Il ritmo narrativo è ideale per chi muove i primi passi nella lingua italiana, permettendo di seguire facilmente la trama senza perdersi nei dettagli linguistici più complessi. Cosa imparerete con questo film? Tantissimo vocabolario della vita quotidiana e della famiglia: mamma, papà, fratello, sorella, amico. Sentirete espressioni semplici come "Vieni qui!" (Come here!), "Ho paura" (I'm scared), "Cosa fai?" (What are you doing?). Inoltre, il film usa principalmente il presente indicativo e il passato prossimo, i due tempi verbali fondamentali per i principianti. Un dettaglio interessante: il film mostra la campagna italiana del Sud, con i suoi paesaggi bellissimi e le case bianche sotto il sole. Imparerete anche come era la vita in Italia negli anni '70, un periodo storico molto particolare. E non preoccupatevi se all'inizio non capite tutto: le immagini e le emozioni dei personaggi vi aiuteranno moltissimo a seguire la storia! Trucco per principianti Guardate il film con i sottotitoli in italiano! Così potrete leggere e ascoltare allo stesso tempo, e il vostro cervello assorbirà le parole più facilmente. Questa tecnica di apprendimento multimodale è scientificamente provata come uno dei metodi più efficaci per l'acquisizione linguistica. 2. "Pane e tulipani" (2000) - Livello A2 Questo è uno dei film italiani più amati! "Pane e tulipani" racconta la storia di Rosalba, una casalinga che viene dimenticata dalla sua famiglia durante una gita turistica. Invece di arrabbiarsi, decide di prendersi una pausa dalla sua vita e va a Venezia, dove inizia una nuova avventura piena di scoperte, incontri inaspettati e possibilità di rinascita personale. Perché è perfetto per il livello A2? Questo film è perfetto per il livello A2 perché i dialoghi sono naturali ma non troppo veloci. I personaggi parlano in modo chiaro e usano un italiano standard, senza dialetti difficili. La trama è facile da seguire e molto coinvolgente: impossibile annoiarsi! La storia lineare permette agli studenti di livello elementare di concentrarsi sulla lingua senza dover decifrare trame complesse o colpi di scena articolati. Cosa imparerete con questo film? Tantissimo vocabolario della vita quotidiana: fare la spesa, cercare casa, parlare con i vicini, ordinare al ristorante. Inoltre, sentirete molte espressioni italiane autentiche, quelle che gli italiani usano veramente tutti i giorni. Per esempio, quando Rosalba dice "Basta!" (Enough!), esprime un sentimento che tutti conosciamo. Imparerete anche frasi utili per le interazioni sociali quotidiane, come salutare, presentarsi, chiedere informazioni e esprimere preferenze. Un dettaglio interessante: il film mostra la bellezza di Venezia in modo poetico. Quindi, oltre a imparare l'italiano, farete anche un viaggio virtuale in una delle città più belle del mondo. Due piccioni con una fava, come diciamo noi in Italia! (Cioè: due risultati con un solo sforzo!) La fotografia del film è straordinaria e cattura l'atmosfera magica della città lagunare in tutte le stagioni. Aspetti culturali importanti Il film offre uno spaccato della società italiana contemporanea, mostrando i ruoli familiari tradizionali e il loro cambiamento. Vedrete come funzionano le pensioni italiane, il sistema dell'ospitalità in piccole pensioni familiari, e la vita quotidiana in una città unica come Venezia. Inoltre, il film esplora temi universali come la ricerca di sé stessi, il coraggio di cambiare e l'importanza dell'amicizia. Livello B1-B2: Intermedi 3. "Tre metri sopra il cielo" (2004) - Livello B1 Questo film è un classico per i giovani italiani! "Tre metri sopra il cielo" è la storia d'amore tra Step, un ragazzo ribelle che ama le moto, e Babi, una ragazza studiosa e tranquilla. È praticamente il "Romeo e Giulietta" moderno italiano! La storia esplora il conflitto tra due mondi diversi, quello della ribellione giovanile e quello delle convenzioni sociali, sullo sfondo della Roma contemporanea. Perché è perfetto per il livello B1? I protagonisti sono adolescenti, quindi il linguaggio è giovane, fresco e pieno di espressioni colloquiali. Imparerete come parlano veramente i giovani italiani, con tutte quelle parole e frasi che non troverete mai nei libri di testo! Per esempio, sentirete espressioni come "Che figata!" (How cool!), "Mi fai impazzire!" (You drive me crazy!), "Non ci posso credere!" (I can't believe it!). I dialoghi sono più veloci rispetto ai film per principianti, ma la storia è così coinvolgente che capirete comunque cosa succede. Inoltre, ci sono molte scene d'azione e di emozione che aiutano a comprendere senza bisogno di capire ogni singola parola. Il linguaggio corporeo e le espressioni facciali degli attori forniscono indizi preziosi per seguire la narrazione. Cosa imparerete con questo film? Il gergo giovanile italiano e le espressioni romantiche che i ragazzi italiani usano per flirtare e dichiarare i propri sentimenti. Imparerete anche vocabolario legato al mondo delle moto, della scuola superiore italiana, delle feste e della vita notturna romana. Il film vi introdurrà all'uso dei diminutivi affettuosi tipici dell'italiano parlato tra giovani, come "amore", "tesoro", "bella". Avvertimento divertente Dopo questo film, potreste sviluppare una strana voglia di comprare una moto e fare corse folli per Roma! Ma per favore, siate responsabili! Il film mostra comportamenti rischiosi che fanno parte della narrativa cinematografica ma che non dovrebbero essere imitati nella vita reale. Tuttavia, la colonna sonora del film, ricca di musica pop italiana e internazionale, è perfetta per creare playlist di studio motivanti. 4. "Metti la nonna in freezer" (2018) - Livello B2 Ora alziamo un po' il livello con una commedia tutta italiana! Claudia è una giovane restauratrice da tempo in crisi lavorativa, che per tirare avanti è costretta a fare affidamento unicamente sulle finanze dell'anziana nonna Birgit. All'improvvisa morte di quest'ultima, per evitare la bancarotta, la ragazza, insieme alle sue amiche e colleghe Rossana e Margie, arriva alla drastica decisione di nascondere e conservare il cadavere della nonna nel freezer, pianificando una truffa per continuare a incassarne la pensione. La situazione degenera quando nella vita di Claudia fa capolino Simone, un maldestro ma incorruttibile maresciallo della Guardia di Finanza, il quale dopo una delusione d'amore si è gettato a capofitto nel lavoro, divenendo per questo l'incubo dei suoi colleghi a causa della sua solerzia. Simone s'innamora a prima vista, cominciando a corteggiare assiduamente la ragazza senza sospettare minimamente della truffa; al contrario, Claudia teme che l'uomo stia indagando su di lei, portandola così, insieme alle amiche, a escogitare vari stratagemmi per tenere nascosta la verità sulla nonna. Perché è perfetto per il livello B2? Questo film rappresenta una sfida linguistica interessante perché mescola italiano standard e linguaggio colloquiale contemporaneo. I dialoghi sono veloci, pieni di riferimenti culturali e di doppi sensi tipici della commedia italiana. Dovrete essere attenti per cogliere tutte le sfumature e l'ironia delle situazioni. La trama intricata richiede una buona comprensione della lingua per seguire i vari colpi di scena e le complicazioni che si susseguono. Cosa imparerete con questo film? Vocabolario legato alla vita quotidiana moderna: problemi economici, affitti, burocrazia italiana (che è famosissima per essere complicata!). Inoltre, imparerete tantissimo sul sistema abitativo italiano, sulla previdenza sociale. Il film introduce anche vocabolario specifico legato alla Guardia di Finanza (la polizia tributaria italiana), ai controlli fiscali, alle pensioni e al sistema burocratico italiano. Sentirete termini tecnici spiegati in contesti pratici che vi aiuteranno a capire come funzionano questi aspetti della società italiana. Curiosità divertente Questo film, nonostante la trama macabra (una nonna morta nel freezer!), è in realtà una commedia dolce e commovente. Gli italiani amano questo tipo di commedie "nere" che mescolano situazioni assurde con emozioni vere. È il tipico umorismo italiano: ridere di situazioni tragiche per renderle più sopportabili! Questa tradizione cinematografica affonda le radici nella commedia all'italiana degli anni '60 e '70, che affrontava temi sociali seri con leggerezza e ironia. Dettagli culturali importanti Il film mostra perfettamente la vita nelle case popolari romane, con i vicini ficcanaso (cioè curiosi,

It's all rhymes and good times in this very special episode of Chat Scene! MC Hammersmith (aka our dear friend Will Naameh) is back again, this time discussing his origins in comedy and hip-hop, and giving us some advanced tips and tricks on rhyming. Join us! --- MC Hammersmith (the alias of Will Naameh), is a multi-award winning hip hop comedian.
He is the world's leading rapper to ever emerge from the ghetto of middle class west London. In his live shows, MC Hammersmith performs improvised hip hop comedy. The lyrics and rhymes of his raps are 100% improvised and based entirely on audience suggestions. In this guise he has won numerous comedy awards, headlined weekends at every major comedy club in the UK, sold out multiple consecutive runs at the Edinburgh Fringe Festival, supported Jason Manford on his live arena tour, and is currently on his third nationwide solo tour. He also writes and performs scripted hip hop comedy tracks, which have gone viral on numerous platforms – most notably racking up over 100 million views on TikTok. He has over 1M followers across social media. He has performed alongside famous hip hop and rap artists – most notably rapping for Dave in a viral “Guess The Musician” Beta Squad video, and being invited to freestyle at R.A. The Rugged Man's London live show. He is also a writer for acclaimed YouTube series Epic Rap Battles of History. Having started comedy as an improvisational comedian, he trained at Second City Chicago, iO, Annoyance, and UCB New York. He still performs improv today, in some of the world's biggest touring improv shows – he can frequently be spotted improvising with Baby Wants Candy, Shamilton, and The Spontaneous Players at the Edinburgh Fringe Festival and across the globe. He has headlined numerous international improv festivals, and was the first person in the UK to perform improv in an arena. @mc_hammersmith Cast: Lily Ludwig, Austin Packard, MC Hammersmith Music Director: Sam Scheidler Drums: Chris Ditton Follow us @CharmScenePod on Instagram, TikTok, and YouTube, join our Discord, or shoot us a message at CharmScenePod@gmail.com!

Are you losing deals because you hate follow-up? In this episode, Chad sits down with Jordan Fleming, co-founder of Smartphone, to bridge the gap between high-tech automation and genuine human connection. Jordan reveals why teaching "skills over scripts" leads to better rapport with sellers and how AI voice agents are evolving from simple tools into a 24/7 labor force.We dive deep into:Why the "money is in the follow-up" is more than just a cliché—and how to automate it without losing the personal touch.The massive shift from "cold calling" to "warm transfers" using AI.Why empathy wins deals: Moving from transactional scripts to "Are you okay?"How to leverage Smartphone to integrate your communications directly with your CRM.Plus, Jordan shares a mind-blowing story about an AI agent showing empathy that you have to hear to believe. If you want to scale your business while reclaiming your freedom, this episode is a must-listen.Jordan is offering a free copy of his book here: Click. Call. Scale.You can also learn more about Jordan on his Instagram and SmrtPhone.IO.Connect with Chad on LinkedIn⁠⁠Follow Chad on Instagram⁠⁠Follow Chad on YouTube⁠⁠Follow True Wealth on Facebook⁠Be sure to leave a rating & review to let us know how this show has helped YOU!Visit our website at ⁠⁠www.TrueWealthInvestors.com⁠⁠ for more real estate wisdom and resources.

Crash DMs for Beth, Ellie, Io, & Jen. This session: The Second Chances take the fight to Sclerora Springweather with a little help from their friends. Follow this series on… RSS: https://aaronbsmith.com/cogwheel/tag/cause-and-effect/feed/ Patreon: https://www.patreon.com/cogwheelgaming Mastodon: https://is.aaronbsmith.com/@cogwheel Not on Mastodon? Consider these instances: gamepad.club dice.camp mastodon.art chirp.enworld.org tabletop.vip MP3 Download: Cause & Effect Ep 70: Finale Music Used: “Pandora’s Box (FB Mix)” by christofori is licensed as Public Domain and can be downloaded from http://modarchive.org Keep us ad free by supporting us on Patreon! Thanks to our current Patreon Patrons (as of this upload…): Cindy (Patron Emeritus), Ellie, Liv Dromen, ShanShen, and Walter!

Authors Drs. Jessica Ross and Alissa Cooper share insights into their JCO PO article, "Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas"  Host Dr. Rafeh Naqash and Drs. Ross and Cooper discuss the landscape of Delta-like ligand 3 (DLL3) and seizure-related homolog protein 6 (SEZ6) across NECs from eight different primary sites. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO PO and an Associate Professor at the OU Health Stephenson Cancer Center. Today, I'm excited to be joined by Dr. Jessica Ross, third-year medical oncology fellow at the Memorial Sloan Kettering Cancer Center, as well as Dr. Alissa Cooper, thoracic medical oncologist at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School. Both are first and last authors of the JCO Precision Oncology article entitled "Clinical and Pathologic Landscapes of Delta-like Ligand 3 and Seizure-Related Homolog Protein 6 or SEZ6 Protein Expression in Neuroendocrine Carcinomas." At the time of this recording, our guest disclosures will be linked in the transcript. Jessica and Alissa, welcome to our podcast, and thank you for joining us today. Dr. Jessica Ross: Thanks very much for having us. Dr. Alissa Cooper: Thank you. Excited to be here. Dr. Rafeh Naqash: It's interesting, a couple of days before I decided to choose this article, one of my GI oncology colleagues actually asked me two questions. He said, "Rafeh, do you know how you define DLL3 positivity? And what is the status of DLL3 positivity in GI cancers, GI neuroendocrine carcinomas?" The first thing I looked up was this JCO article from Martin Wermke. You might have seen it as well, on obrixtamig, a phase 1 study, a DLL3 bi-specific T-cell engager. And they had some definitions there, and then this article came along, and I was really excited that it kind of fell right in place of trying to understand the IHC landscape of two very interesting targets. Since we have a very broad and diverse audience, especially community oncologists, trainees, and of course academic clinicians and some people who are very interested in genomics, we'll try to make things easy to understand. So my first question for you, Jessica, is: what is DLL3 and SEZ6 and why are they important in neuroendocrine carcinomas? Dr. Jessica Ross: Yeah, good question. So, DLL3, or delta-like ligand 3, is a protein that is expressed preferentially on the tumor cell surface of neuroendocrine carcinomas as opposed to normal tissue. It is a downstream target of ASCL1, and it's involved in neuroendocrine differentiation, and it's an appealing drug target because it is preferentially expressed on tumor cell surfaces. And so, it's a protein, and there are several drugs in development targeting this protein, and then Tarlatamab is an approved bi-specific T-cell engager for the treatment of extensive-stage small cell lung cancer in the second line. SEZ6, or seizure-like homolog protein 6, is a protein also expressed on neuroendocrine carcinoma cell surface. Interestingly, so it's expressed on neuronal cells, but its exact role in neuroendocrine carcinomas and oncogenesis is actually pretty poorly understood, but it was identified as an appealing drug target because, similarly to DLL3, it's preferentially expressed on the tumor cell surface. And so this has also emerged as an appealing drug target, and there are drugs in development, including antibody-drug conjugates, targeting this protein for that reason. Dr. Alissa Cooper: Over the last 10 to 15 years or so, there's been an increasing focus on precision oncology, finding specific targets that actually drive the cancer to grow, not just within lung cancer but in multiple other primary cancers. But specifically, at least speaking from a thoracic oncology perspective, the field of non-small cell lung cancer has completely exploded over the past 15 years with the discovery of driver oncogenes and then matched targeted therapies. Within the field of neuroendocrine carcinomas, including small cell lung cancer but also other high-grade neuroendocrine carcinomas, there has not been the same sort of progress in terms of identifying targets with matched therapies. And up until recently, we've sort of been treating these neuroendocrine malignancies kind of as a monolithic disease process. And so recently, there's been sort of an explosion of research across the country and multiple laboratories, multiple people converging on the same open questions about why might patients with specific tumor biologies have different kind of responses to different therapies. And so first this came from, you know, why some patients might have a good response to chemo and immunotherapy, which is the first-line approved therapy for small cell lung cancer, and we also sort of extrapolate that to other high-grade neuroendocrine carcinomas. What's the characteristic of that tumor biology? And at the same time, what are other targets that might be identifiable? Just as Jesse was saying, they're expressed on the cell surface, they're not necessarily expressed in normal tissue. Might this be a strategy to sort of move forward and create smarter therapies for our patients and therefore move really into a personalized era for treatment for each patient? And that's really driving, I think, a lot of the synthesis of this work of not only the development of multiple new therapies, but really understanding which tumor might be the best fit for which therapy. Dr. Rafeh Naqash: Thank you for that explanation, Alissa. And as you mentioned, these are emerging targets, some more further along in the process with approved drugs, especially Tarlatamab. And obviously, DLL3 was something identified several years back, but drug development does take time, and readout for clinical trials takes time. Could you, for the sake of our audience, try to talk briefly about the excitement around Tarlatamab in small cell lung cancer, especially data that has led to the FDA approval in the last year, year and a half? Dr. Alissa Cooper: Sure. Yeah, it's really been an explosion of excitement over, as you're saying, the last couple of years, and work really led by our mentor, Charlie Rudin, had identified DLL3 as an exciting target for small cell lung cancer specifically but also potentially other high-grade neuroendocrine malignancies. Tarlatamab is a DLL3-targeting bi-specific T-cell engager, which targets DLL3 on the small cell lung cancer cells as well as CD3 on T cells. And the idea is to sort of introduce the cancer to the immune system, circumventing the need for MHC class antigen presentation, which that machinery is typically not functional in small cell lung cancer, and so really allowing for an immunomodulatory response, which had not really been possible for most patients with small cell lung cancer prior to this. Tarlatamab was tested in a phase 2 registrational trial of about 100 patients and demonstrated a response rate of 40%, which was very exciting, especially compared with other standard therapies which were available for small cell lung cancer, which are typically cytotoxic therapies. But most excitingly, more than even the response rate, I think, in our minds was the durability of response. So patients whose disease did have a response to Tarlatamab could potentially have a durable response lasting a number of months or even over a year, which had previously not ever been seen in this in the relapsed/refractory setting for these patients. I think the challenge with small cell lung cancer and other high-grade neuroendocrine malignancies is that a response to therapy might be a bit easier to achieve, but it's that durability. The patient's tumors really come roaring back quite aggressively pretty quickly. And so this was sort of the most exciting prospect is that durability of response, that long potential overall survival tail of the curve really being lifted up. And then most recently at ASCO this year, Dr. Rudin presented the phase 3 randomized controlled trial which compared Tarlatamab to physician's choice of chemotherapy in a global study. And the choice of chemotherapy did vary depending on the part of the world that the patients were enrolled in, but in general, it was a really markedly positive study for response rate, for progression-free survival, and for overall survival. Really exciting results which really cemented Tarlatamab's place as the standard second-line therapy for patients with small cell lung cancer whose disease has progressed on first-line chemo-immunotherapy. So that has been very exciting. This drug was FDA approved in May of 2024, and so has been used extensively since then. I think the adoption has been pretty widespread, at least in the US, but now in this global trial that was just presented, and there was a corresponding New England Journal paper, I think really confirms that this is something we really hopefully can offer to most of our patients. And I think, as we all know, that this therapy or other therapies like it are also being tested potentially in the first-line setting. So there was data presented with Tarlatamab incorporated into the maintenance setting, which also showed exciting results, albeit in a phase 1 trial, but longer overall survival than we're used to seeing in this patient population. And we await results of the study that is incorporating Tarlatamab into the induction phase with chemotherapy as well. So all of this is extraordinarily exciting for our patients to sort of move the needle of how many patients we can keep alive, feeling functional, feeling well, for as long as possible. Dr. Rafeh Naqash: Very exciting session at ASCO. I was luckily one of the co-chairs for the session that Dr. Rudin presented it, and I remember somebody mentioning there was more progress seen in that session for small cell lung cancer than the last 30, 35 years for small cell, very exciting space and time to be in as far as small cell lung cancer. Now going to this project, Jessica, since you're the first author and Alissa's the last, I'm assuming there was a background conversation that you had with Alissa before you embarked on this project as an idea. So could you, again, for other trainees who are interested in doing research, and it's never easy to do research as a resident and a fellow when you have certain added responsibilities. Could you give us a little bit of a background on how this started and why you wanted to look at this question? Dr. Jessica Ross: Yeah, sure. So, as with many exciting research concepts, I think a lot of them are derived from the clinic. And so I think Alissa and I both see a good number of patients with small cell, large cell lung cancer, and then high-grade neuroendocrine carcinomas. And so I think this was really born out of a basic conversation of we have these drugs in development targeting these two proteins, DLL3 and SEZ6, but really what is the landscape of cancers that express these proteins and who are the patients that really might benefit from these exciting new therapies. And of course, there was some data out there, but sort of less than one would imagine in terms of, you know, neuroendocrine carcinomas can really come from anywhere in the body. And so when you're seeing a patient with small cell of the cervix, for example, like what are the chances that their cancer expresses DLL3 or expresses SEZ6? So it was really derived from this pragmatic, clinically oriented question that we had both found ourselves thinking about, and we were lucky enough at MSK, we had started systematically staining patients' tumors for DLL3, tumors that are high-grade neuroendocrine carcinomas, and then we had also more recently started staining for SEZ6 as well. And so we had this nice prospectively collected dataset with which to answer this question. Dr. Rafeh Naqash: Excellent. And Alissa, could you try to go into some of the details around which patients you chose, how many patients, what was the approach that you selected to collect the data for this project? Dr. Alissa Cooper: This is perhaps a strength but also maybe a limitation of this dataset is, as Jesse alluded to, our pathology colleagues are really the stars of this paper here because we were lucky enough at MSK that they were really forethinking. They are absolute experts in the field and really forward-thinking people in terms of what information might be needed in the future to drive treatment decision-making. And so, as Jesse had said, small cell lung cancer tumor samples reflexively are stained for DLL3 and SEZ6 at MSK if there's enough tumor tissue. The other high-grade neuroendocrine carcinomas, those stains are performed upon physician request. And so that is a bit of a mixed bag in terms of the tumor samples we were able to include in this dataset because, you know, upon physician request depends on a number of factors, but actually at MSK, a number of physicians were requesting these stains to be done on their patients with high-grade neuroendocrine cancers of of other histologies. So we looked at all tumor samples with a diagnosis of high-grade neuroendocrine carcinoma of any histology that were stained for these two stains of interest. You know, I can let Jesse talk a bit more about the methodology. She was really the driver of this project. Dr. Jessica Ross: Yeah, sure. So we had 124 tumor samples total. All of those were stained for DLL3, and then a little less than half, 53, were stained for SEZ6. As Alissa said, they were from any primary site. So about half of them were of lung origin, that was the most common primary site, but we included GI tract, head and neck, GU, GYN, even a few tumors of unknown origin. And again, that's because I think a lot of these trials are basket trials that are including different high-grade neuroendocrine carcinomas no matter the primary site. And so we really felt like it was important to be more comprehensive and inclusive in this study. And then, methodologically, we also defined positivity in terms of staining of these two proteins as anything greater than or equal to 1% staining. There's really not a defined consensus of positivity when it comes to these two novel targets and staining for these two proteins. But in the Tarlatamab trials, for some of the correlative work that's been done, they use that 1% cutoff, and we just felt like being consistent with that and also using a sort of more pragmatic yes/no cutoff would be more helpful for this analysis. Dr. Alissa Cooper: And that was a point of discussion, actually. We had contemplated multiple different schemas, actually, for how to define thresholds of positivity. And I know you brought up that question before, what does it mean to be DLL3 positive or DLL3 high? I think you were alluding to prior that there was a presentation of obrixtamig looking at extra-pulmonary neuroendocrine carcinomas, and they actually divvied up the results between DLL3 50% or greater versus DLL3 low under 50%. And they actually did demonstrate differential efficacy certainly, but also some differential safety as well, which is very provocative and that kind of analysis has not been presented for other novel therapies as far as I'm aware. I could be wrong, but as far as I'm aware, that was sort of the first time that we saw a systematic presentation of considering patients to be, quote unquote, "high" or "low" in these sort of novel targets. I think it is important because the label for Tarlatamab does not require any DLL3 expression at all, actually. So it's not hinging upon DLL3 expression. They depend on the fact that the vast majority of small cell lung cancer tumors do express DLL3, 85% to 90% is what's been demonstrated in a few studies. And so, there's not prerequisite testing needed in that regard, but maybe for these extra-pulmonary, other histology neuroendocrine carcinomas, maybe it does matter to some degree. Dr. Rafeh Naqash: Definitely agree that this evolving landscape of trying to understand whether an expression for something actually really does correlate with, whether it's an immune cell engager or an antibody-drug conjugate is a very evolving and dynamically moving space. And one of the questions that I was discussing with one of my friends was whether IHC positivity and the level of IHC positivity, as you've shown in one of those plots where you have double positive here on the right upper corner, you have the double negative towards the left lower, whether that somehow determines mRNA expression for DLL3. Obviously, that was not the question here that you were looking at, but it does kind of bring into question certain other aspects of correlations, expression versus IHC. Now going to the figures in this manuscript, very nicely done figures, very easy to understand because I've done the podcast for quite a bit now, and usually what I try to do first is go through the figures before I read the text, and and a lot of times it's hard to understand the figures without reading the text, but in your case, specifically the figures were very, very well done. Could you give us an overview, a quick overview of some of the important results, Jessica, as far as what you've highlighted in the manuscript? Dr. Jessica Ross: Sure. So I think the key takeaway is that, of the tumors in our cohort, the majority were positive for DLL3 and positive for SEZ6. So about 80% of them were positive for DLL3 and 80% were positive for SEZ6. About half of the tumors were stained for both proteins, and about 65% of those were positive as well. So I think if there's sort of one major takeaway, it's that when you're seeing a patient with a high-grade neuroendocrine carcinoma, the odds are that their tumor will express both of these proteins. And so that can sort of get your head thinking about what therapies they might be eligible for. And then we also did an analysis of some populations of interest. So for example, we know that non-neuroendocrine pathologies can transform into neuroendocrine tumors. And so we specifically looked at that subset of patients with transformed tumors, and those were also- the majority of them were positive, about three-quarters of them were positive for both of these two proteins. We looked at patients with brain met samples, again, about 70% were positive. And then I'd say the last sort of population of interest was we had a subset of 10 patients who had serial biopsies stained for either DLL3 or SEZ6 or both. In between the two samples, these patients were treated with chemotherapy. They were not treated with targeted therapy, but interestingly, in the majority of cases, the testing results were concordant, meaning if it was DLL3 positive to begin with, it tended to remain DLL3 positive after treatment. And so I think that's important as well as we think about, you know, a patient who maybe had DLL3 testing done before they received their induction chemo-IO, we can somewhat confidently say that they're probably still DLL3 positive after that treatment. And then finally, we did do a survival analysis among specifically the patients with lung neuroendocrine carcinomas. We looked at whether DLL3 expression affected progression-free survival on first-line platinum-etoposide, and then we looked at did it affect overall survival. And we found that it did not have an impact or the median progression-free survival was similar whether you were DLL3 positive or negative. But interestingly, with overall survival, we found that DLL3 positivity actually correlated with slightly improved overall survival. These were small numbers, and so, you know, I think we have to interpret this with caution, for sure, but it is interesting. I think there may be something to the fact that five of the patients who were DLL3 positive were treated with DLL3-targeting treatments. And so this made me think of, like in the breast cancer world, for example, if you have a patient with HER2-positive disease, it initially portended worse prognosis, more aggressive disease biology, but on the other hand, it opens the door for targeted treatments that actually now, at least with HER2-positive breast cancer, are associated with improved outcomes. And so I think that's one finding of interest as well. Dr. Rafeh Naqash: Definitely proof-of-concept findings here that you guys have in the manuscript. Alissa, if I may ask you, what is the next important step for a project like this in your mind? Dr. Alissa Cooper: Jesse has highlighted a couple of key findings that we hope to move forward with future investigative studies, not necessarily in a real-world setting, but maybe even in clinical trial settings or in collaboration with sponsors. Are these biomarkers predictive? Are they prognostic? You know, those are still- we have some nascent data, data has been brewing, but I think that we we still don't have the answers to those open questions, which I think are critically important for determining not only clinical treatment decision-making, but also our ability to understand sequencing of therapies, prioritization of therapies. I think a prospective, forward-looking project, piggybacking on that paired biopsy, you know, we had a very small subset of patients with paired biopsies, but a larger subset or cohort looking at paired biopsies where we can see is there evolution of these IHC expression, even mRNA expression, as you're saying, is there differential there? Are there selection pressures to targeted therapies? Is there upregulation or downregulation of targets in response not just to chemotherapy, but for example, for other sort of ADCs or bi-specific T-cell engagers? I think those are going to be critically important future studies which are going to be a bit challenging to do, but really important to figure out this key clinical question of sequencing, which we're all contemplating in our clinics day in and day out. If you have a patient, and these patients often can be sick quite quickly, they might have one shot of what's the next treatment that you're going to pick. We can't guarantee that every patient is going to get to see every therapy. How can you help to sort of answer the question of like what should you offer? So I think that's the key question sort of underlying any future work is how predictive or prognostic are these biomarkers? What translational or correlative studies can we do on the tissue to understand clinical treatment decision-making? I think those are the key things that will unfold in the next couple of years. Dr. Rafeh Naqash: The last question for you, Alissa, that I have is, you are fairly early in your career, and you've accomplished quite a lot. One of the most important things that comes out from this manuscript is your mentorship for somebody who is a fellow and who led this project. For other junior investigators, early-career investigators, how did you do this? How did you manage to do this, and how did you mentor Jessica on this project with some of the lessons that you learned along the way, the good and other things that would perhaps help other listeners as they try to mentor residents, trainees, which is one of the important things of what we do in our daily routine? Dr. Alissa Cooper: I appreciate you calling me accomplished. Um, I'm not sure how true that is, but I appreciate that. I didn't have to do a whole lot with this project because Jesse is an extraordinarily smart, driven, talented fellow who came up with a lot of the clinical questions and a lot of the research questions as well. And so this project was definitely a collaborative project on both of our ends. But I think what was helpful from both of our perspectives is from my perspective, I could kind of see that this was a gap in the literature that really, I think, from my work leading clinical trials and from treating patients with these kinds of cancers that I really hoped to answer. And so when I came to Jessica with this idea as sort of a project to complete, she was very eager to take it and run with it and also make it her own. You know, in terms of early mentorship, I have to admit this was the first project that I mentored, so it was a great learning experience for me as well because as an early-career clinician and researcher, you're used to having someone else looking over your shoulder to tell you, "Yes, this is a good journal target, here's what we can anticipate reviewers are going to say, here are other key collaborators we should include." Those kind of things about a project that don't always occur to you as you're sort of first starting out. And so all of that experience for me to be identifying those more upper-level management sort of questions was a really good learning experience for me. And of course, I was fantastically lucky to have a partner in Jesse, who is just a rising star. Dr. Jessica Ross: Thank you. Dr. Rafeh Naqash: Well, excellent. It sounds like the first of many other mentorship opportunities to come for you, Alissa. And Jessica, congratulations on your next step of joining and being faculty, hopefully, where you're training. Thank you again, both of you. This was very insightful. I definitely learned a lot after I reviewed the manuscript and read the manuscript. Hopefully, our listeners will feel the same. Perhaps we'll have more of your work being published in JCO PO subsequently. Dr. Alissa Cooper: Hope so. Thank you very much for the opportunity to chat today. Dr. Jessica Ross: Yes, thank you. This was great. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so as you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Disclosures: Dr. Alissa Jamie Cooper Honoraria Company: MJH Life Scienes, Ideology Health, Intellisphere LLC, MedStar Health, Physician's Education Resource, LLC,  Gilead Sciences, Regeneron, Daiichi Sankyo/Astra Zeneca, Novartis,  Research Funding: Merck, Roche, Monte Rosa Therapeutics, Abbvie, Amgen, Daiichi Sankyo/Astra Zeneca Travel, Accommodations, Expenses: Gilead Sciences

In this episode of Improv and Magic, we spotlight the transformative world of improvisation with guest Jill Eickmann, co-founder and Artistic Director of Leela Improv Theatre. Known for her holistic approach to improv, Jill shares insights on ensemble building, truthful artistic play, and the healing power of performance.Jill Eickmann is a nationally recognized improvisational theatre artist, director, and educator. She co-founded Leela Improv, a bi-coastal training center and theatre company based in San Francisco and Raleigh. With over 20 years of experience, Jill has designed Leela's seven-level improv curriculum, rooted in authenticity, collaboration, and joyful play.Her background includes an MA in Drama Therapy from the California Institute of Integral Studies, training with renowned institutions such as iO, Annoyance Theatre, and Upright Citizens Brigade, and corporate workshops for companies like Google, YouTube, Facebook, IBM, Visa, and McKinsey & Company.Beyond teaching, Jill is a performer and drama therapist who integrates improvisation with therapeutic practices, emphasizing connection, creativity, and self-expression.In this episode, Jill discusses the mission of Leela Improv: truthful, artistic play that blends authenticity with ensemble-driven creativity. She explores how improv fosters community, risk-taking, and resilience, both on stage and in everyday life. Jill shares her journey from studying acting and drama therapy to building one of the most respected improv training centers in the U.S.Tune in to hear Jill Eickmann's inspiring perspective on improvisation as both an art form and a tool for personal growth. This episode is a must-listen for anyone passionate about improv, theatre, or creative collaboration.Find out more about Jill at jilleickmann.com, and follow Leela Improv Theater at leela-nc.com.Don't forget to like and review! For more information on LD Madera and how you can sponsor an episode of Improv and Magic, visit ldmadera.com.

Get PUMPED. This week we're joined by charming guest and UK's thickest boy - MC Hammersmith! It's a fully improvised musical, complete with melodious mayors, brutish boys, critical crosswords and more! Get your reps in on this all new Charm Scene! LADS LADS LADS. --- MC Hammersmith (the alias of Will Naameh), is a multi-award winning hip hop comedian.
He is the world's leading rapper to ever emerge from the ghetto of middle class west London. In his live shows, MC Hammersmith performs improvised hip hop comedy. The lyrics and rhymes of his raps are 100% improvised and based entirely on audience suggestions. In this guise he has won numerous comedy awards, headlined weekends at every major comedy club in the UK, sold out multiple consecutive runs at the Edinburgh Fringe Festival, supported Jason Manford on his live arena tour, and is currently on his third nationwide solo tour. He also writes and performs scripted hip hop comedy tracks, which have gone viral on numerous platforms – most notably racking up over 100 million views on TikTok. He has over 1M followers across social media. He has performed alongside famous hip hop and rap artists – most notably rapping for Dave in a viral “Guess The Musician” Beta Squad video, and being invited to freestyle at R.A. The Rugged Man's London live show. He is also a writer for acclaimed YouTube series Epic Rap Battles of History. Having started comedy as an improvisational comedian, he trained at Second City Chicago, iO, Annoyance, and UCB New York. He still performs improv today, in some of the world's biggest touring improv shows – he can frequently be spotted improvising with Baby Wants Candy, Shamilton, and The Spontaneous Players at the Edinburgh Fringe Festival and across the globe. He has headlined numerous international improv festivals, and was the first person in the UK to perform improv in an arena. @mc_hammersmith --- Cast: Lily Ludwig, Austin Packard, MC Hammersmith Music Director: Sam Scheidler Drums: Chris Ditton Follow us @CharmScenePod on Instagram, TikTok, and YouTube, join our Discord, or shoot us a message at CharmScenePod@gmail.com!"

In this episode, we welcome Autumn Durald Arkapaw, ASC. Autumn has shot films including Sinners, The Last Showgirl, Black Panther: Wakanda Forever, Beastie Boys Story, “Loki” and Palo Alto. In our chat, she shares about her roots, early cinematic inspirations, pathway into filmmaking, and how she approached the cinematography of Sinners. Autumn also talks about working with IMAX cameras, her lens choices, and other insights into the making of this standout film of 2025.“The Making Of” is presented by AJA:UDC-4K: More than just an average 12G-SDI and HDMI up/down/cross converterAJA's newest Mini-Converter boasts powerful 12G-SDI and HDMI 2.0 I/O, 4K/UltraHD/2K/HD scaling, frame sync, frame rate conversion, and more. Unlocking an expansive range of conversion possibilities, UDC-4K enables teams to get disparate sources into a common format and timing reference. Explore how UDC-4K solves some of the most common production and post challenges here.Shoot. Store. Secure. Smile.The OWC Guardian is a bus‑powered, portable NVMe SSD featuring 256‑bit AES OPAL hardware encryption and a color touch‑screen for intuitive, secure access. With up to 1,000 MB/s real‑world transfer speeds, platform‑agnostic operation (Mac, PC, iPad Pro), and a rugged anodized aluminum enclosure, it's built to protect audit‑sensitive media and projects anytime, anywhere. Learn more hereMeet Stream Deck Studio:Meet Stream Deck Studio, the ultimate control surface designed for professional broadcast and live production environments. Built on the iconic Elgato hardware and powered by Bitfocus software, it offers a hyper-customizable experience that simplifies even the most complex workflows. With compatibility across hundreds of devices from the industry's top vendors, Stream Deck Studio gives you complete command over your production setup, making it easier than ever to create seamless, high-quality broadcasts. Call Videoguys at 800-323-2325 to learn more and take your production control to the next level today! Explore hereWomen in Media — Holiday Toast 2025Dec 6th | 10am – 2pmHotel Sofitel | Beverly Hills, CAJoin Women In Media as we raise a glass to legendary women of the entertainment industry. There will be a champagne brunch, silent auction, panel with honorees, and celebratory toasts by their toastmasters.Holiday Toast 2025 Honorees include Ashley Nicole Black, Writer/Actor (Shrinking, Ted Lasso, A Black Lady Sketch Show), Toastmaster Chelsea Devantez, Comedian, Writer (The Problem with John Stewart, Girls5Eva), Krystina Figg, Best Boy Grip, Grip (Superman, Killers of the Flower Moon, Dunkirk), and Mandy Walker, AM, ACS, ASC, Director of Photography (Elvis, Hidden Figures, Mulan), President of the American Society of Cinematographers. Get tickets and tables herePodcast Rewind:Nov. 2025 - Ep. 104…Advertise in this newsletter and reach 250K film and TV industry professionals each week. For more information, please email mvalinsky@me.com Get full access to The Making Of at themakingof.substack.com/subscribe

Vorresti ricevere notizie, saluti, auguri dalle Apostole della Vita Interiore?Lasciaci i tuoi contatti cliccando il link qui sotto e con la nostra nuova rubrica digitale potremo raggiungerti.https://www.it.apostlesofil.com/database/- Premi il tasto PLAY per ascoltare la catechesi del giorno e condividi con altri se vuoi -+ Dal Vangelo secondo Luca +In quel tempo, Gesù disse una parabola, perché era vicino a Gerusalemme ed essi pensavano che il regno di Dio dovesse manifestarsi da un momento all'altro.Disse dunque: «Un uomo di nobile famiglia partì per un paese lontano, per ricevere il titolo di re e poi ritornare. Chiamati dieci dei suoi servi, consegnò loro dieci monete d'oro, dicendo: "Fatele fruttare fino al mio ritorno". Ma i suoi cittadini lo odiavano e mandarono dietro di lui una delegazione a dire: "Non vogliamo che costui venga a regnare su di noi". Dopo aver ricevuto il titolo di re, egli ritornò e fece chiamare quei servi a cui aveva consegnato il denaro, per sapere quanto ciascuno avesse guadagnato.Si presentò il primo e disse: "Signore, la tua moneta d'oro ne ha fruttate dieci". Gli disse: "Bene, servo buono! Poiché ti sei mostrato fedele nel poco, ricevi il potere sopra dieci città".Poi si presentò il secondo e disse: "Signore, la tua moneta d'oro ne ha fruttate cinque". Anche a questo disse: "Tu pure sarai a capo di cinque città".Venne poi anche un altro e disse: "Signore, ecco la tua moneta d'oro, che ho tenuto nascosta in un fazzoletto; avevo paura di te, che sei un uomo severo: prendi quello che non hai messo in deposito e mieti quello che non hai seminato". Gli rispose: "Dalle tue stesse parole ti giudico, servo malvagio! Sapevi che sono un uomo severo, che prendo quello che non ho messo in deposito e mieto quello che non ho seminato: perché allora non hai consegnato il mio denaro a una banca? Al mio ritorno l'avrei riscosso con gli interessi". Disse poi ai presenti: "Toglietegli la moneta d'oro e datela a colui che ne ha dieci". Gli risposero: "Signore, ne ha già dieci!". "Io vi dico: A chi ha, sarà dato; invece a chi non ha, sarà tolto anche quello che ha. E quei miei nemici, che non volevano che io diventassi loro re, conduceteli qui e uccideteli davanti a me"».Dette queste cose, Gesù camminava davanti a tutti salendo verso Gerusalemme.Parola del Signore.

Topics covered in this episode: Possibility of a new website for Django aiosqlitepool deptry browsr Extras Joke Watch on YouTube About the show Sponsored by us! Support our work through: Our courses at Talk Python Training The Complete pytest Course Patreon Supporters Connect with the hosts Michael: @mkennedy@fosstodon.org / @mkennedy.codes (bsky) Brian: @brianokken@fosstodon.org / @brianokken.bsky.social Show: @pythonbytes@fosstodon.org / @pythonbytes.fm (bsky) Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Brian #1: Possibility of a new website for Django Current Django site: djangoproject.com Adam Hill's in progress redesign idea: django-homepage.adamghill.com Commentary in the Want to work on a homepage site redesign? discussion Michael #2: aiosqlitepool

In episode 109, we sit down with Drs. Ian Katz and Shelly Rauvola, co-editors of a groundbreaking special issue in Industrial and Organizational Psychology. Together, we explore how current public policy changes in the United States are reshaping the world of work, from employee well-being and marginalized worker experiences to the future of I-O psychology education and research.Key takeaways include:* How policy changes impact HR practices, training, and organizational functioning* The chilling effect of political climates on academic freedom and research* Why behavioral scientists must engage in policy conversations* How I-O psychology can respond using existing theories and evidence-based practices* A call to action for researchers and practitioners to advocate for worker dignity and evidence-based decision-makingThis episode is essential listening for anyone invested in the future of work, science advocacy, and the role of IO psychology in shaping policy.Find the special issue here: https://www.cambridge.org/core/journals/industrial-and-organizational-psychology/issue/380836BA2B93123CE626AACDCB5DF7DAFind Ian Katz here: https://csh.depaul.edu/faculty-staff/faculty-a-z/Pages/psychology/ian-katz.aspxFind Shelly Rauvola here: https://csh.depaul.edu/faculty-staff/faculty-a-z/Pages/psychology/shelly-rauvola.aspx This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit healthywork.substack.com

Margaret continues talking with Io about the Iceni revolt of 61 AD that almost drove Rome out of Britain. Sources: https://www.jstor.org/stable/4434717 https://ul.qucosa.de/api/qucosa%3A31804/attachment/ATT-0/ https://web.archive.org/web/20120612044230/http://www.britarch.ac.uk/ba/ba83/feat3.shtml https://penelope.uchicago.edu/Thayer/E/Roman/Texts/Cassius_Dio/62*.html#2 https://www.perseus.tufts.edu/hopper/text?doc=Perseus%3Atext%3A1999.02.0078%3Abook%3D14%3Achapter%3D32 https://historyandarchaeologyonline.com/the-evidence-for-the-historical-boudica%ef%bf%bc%ef%bf%bc/ https://vridar.org/2018/05/07/doing-history-how-do-we-know-queen-boadicea-boudicca-existed/ https://www.jstor.org/stable/25471937 http://simoneparrish.com/2016/07/how-i-woad-using-woad-for-body-painting/See omnystudio.com/listener for privacy information.

Margaret talks with Io about the Iceni revolt of 61 AD that almost drove Rome out of Britain. Sources: https://www.jstor.org/stable/4434717 https://ul.qucosa.de/api/qucosa%3A31804/attachment/ATT-0/ https://web.archive.org/web/20120612044230/http://www.britarch.ac.uk/ba/ba83/feat3.shtml https://penelope.uchicago.edu/Thayer/E/Roman/Texts/Cassius_Dio/62*.html#2 https://www.perseus.tufts.edu/hopper/text?doc=Perseus%3Atext%3A1999.02.0078%3Abook%3D14%3Achapter%3D32 https://historyandarchaeologyonline.com/the-evidence-for-the-historical-boudica%ef%bf%bc%ef%bf%bc/ https://vridar.org/2018/05/07/doing-history-how-do-we-know-queen-boadicea-boudicca-existed/ https://www.jstor.org/stable/25471937 http://simoneparrish.com/2016/07/how-i-woad-using-woad-for-body-painting/See omnystudio.com/listener for privacy information.